
# Beyond IVUS: OCT, NIRS, and Beyond

# Akiko Maehara, MD

Cardiovascular Research Foundation/ Columbia University Medical Center New York City, NY






# **Conflict of Interest Disclosure**

- Akiko Maehara
  - Personal: Consultant for ACIST, Boston Scientific Corporation
  - Cardiovascular Research Foundation: Boston Scientific Corporation









# - in vivo Pathology -





# Unstable Plaque=Causing ThrombosisPlaque RupturePlaque ErosionCalcified Nodule









## Stable Plaque=Not Causing Thrombosis


#### Fibrocalcific Plaque




Pathological Intimal Thickening








#### Post-Thrombectomy



# Representative Case of Rupture








MEDICAL CENTER

# OCT Thin Capped Fibroatheroma (OCT-TCFA)

### • Description:

- OCT-delineated necrotic core
- Overlying fibrous cap
- Minimum thickness of the fibrous cap is less than a predetermined threshold
- Level of Evidence: High
- Unknown:
  - Relevance of number of quadrants



TD-OCT; Takashi Akasaka, Wakayama; Lightlab/St. Jude M2 system.






# Macrophage Accumulations

## Description:

- Defined only in plaque
- Signal-rich, distinct or confluent punctate regions
- Exceed the intensity of background noise
- Can create shadows

### Level of Evidence: Med

- Unknown:
  - IVOCT ability to discriminate microcalcifications from macrophages




FD-OCT, Guillermo Tearney, MGH and Evelope Regark FRMSbyterian MGH prototype system.

Tearney at ACC 2014


# **EASY-FIT Study**

- Single center, randomized Atrovastatin 20mg vs 5mg in non-treated HL pts
- Intermediate non-culprit lesion in culprit vessel
- Fibrous cap thickness by OCT at 12 month
- 30 pts in each cohort



# **OCT Erosion: Level of Evidence Low**

### **Definite OCT-Erosion**



#### Presence of attached thrombus overlying an intact and visualized plaque

### **Probable OCT-Erosion**




Figure 3


- 1) Luminal surface irregularity without thrombus
- Attenuation of underlying plaque by thrombus without superficial lipid or calcification immediately proximal or distal siterk-Presbyterian



JACC Jia H, et al. 2013

### **Erosion - Thrombus in the Absence of Rupture**

34-year old man with history of smoking and untreated hyperlipidemia, had epigastric pain and was found dead at home






OCRF CARDIOVASCULAR RESEARCH FOUNDATION At the heart of innovation

Joner M at CRT 2015

# **Calcified Nodule**






Hao et al, JACC Interv 2014

- NewYork-Presbyterian


# Representative Case with Calcified Nodule






- NewYork-Presbyterian

### **TCFA with Intraplaque Hemorrhage**



Joner M CRT 2015

### **Healed Plaque Rupture**




and Physiology 2015: A Clinical Workshop

Joner M CRT 2015


# **Neoatherosclerosis**

Macrophage infiltration on luminal surface



#### TCFA within neointima

**9**CRF





MBIA UNIVERSITY CAL CENTER


Nakano et al. JACC Img 2012; 5: 71-82.



# - Tool for PCI Guidance -









# **Difference between OCT and IVUS**


#### Malapposition









OCT








Columbia University Medical Center

- NewYork-Presbyterian




OCT protocol to guide PCI Optimal PCI criteria

# Primary endpoint: Minimum stent area by OCT

- Non-inferiority compared to IVUS arm
- Superiority compared to Angio arm


PI: Ziad Ali, Chair: Gregg Stone Sponsor: St Jude Medical






# - Prediction of Outcome -






### NIR can Distinguish Lipid-rich from Fibrotic Plaques



#### 64 year old presents with STEMI in March 2012

#### Unstable angina October 2012







# Methods

#### Spectrum NIRS-IVUS Registry


- Single center, observational
- Prospectively enrolled patients undergoing NIRS-IVUS

#### Inclusion criteria

 Patients completing ≥1 year of follow-up

#### <u>Exclusion criteria</u>

- Prior CABG/referred for CABG
- Uninterpretable NIRS
- NIRS imaging performed only within a stented segment








# Methods

- Evaluated non-stented coronary segments for large LRP
  - defined as a maxLCBI<sub>4mm</sub> ≥500
- Patients followed for MACCE
  - Composite of all-cause mortality, recurrent ACS requiring revascularization, or acute cerebrovascular events
- Events related to previously stented segments were excluded
- All events adjudicated blinded to the NIRS-IVUS imaging








# Results

#### **Baseline NIRS Findings**

- 462 non-overlapping 10-mm coronary segments analyzed
- A large LRP was detected in 15 (3.2%) segments & in 12 (9.9%) patients



### Follow Up Events


- Average follow-up duration was 603 ± 145 days (1.7 years)
- MACCE (unrelated to previously stented segments) occurred in 11.6% of patients during follow up
  - All-cause death 4.1%
  - ACS requiring revascularization 6.6%
  - ➡ CVA 0.8%



Frederik Meijer Heart & Vascular Institute



# Large LRP by NIRS and MACCE




<u>MACCE Rate</u> Large LRP 58.3% vs No large LRP 6.4% (p<0.001)

> ACS Requiring Revascularization Large LRP 25.0% vs No large LRP 4.6% (p<0.001)


# Relationship between Lipid Rich Plaque detected by NIRS and Outcomes

- Prospective Single Center Study, 206 patients (ACS47%)
- Primary Endpoint: Composite of all-cause mortality, nonfatal ACS, stroke and unplanned PCI during one-year FU
- >40mm non culprit segment of NIRS

### Lipid Core Burden Index (LCBI)=188








Oemrawsingh RM et al, JACC 2015

# Relationship between Lipidic Plaque detected by NIRS and Outcomes

Primary Endpoint: Adjusted Hazard Ratio = 4.0 (1.3-12.3), p=0.01




Columbia University Medical Center PROSPECT II Study 900 pts with ACS at up to 20 hospitals in Sweden, Denmark and Norway (SCAAR) NSTEMI or STEMI >12° IVUS + NIRS (blinded) performed in culprit vessel(s) Successful PCI of all intended lesions (by angio ±FFR/iFR)

**Formally enrolled** 

### **3-vessel imaging post PCI**


Culprit artery, followed by non-culprit arteries Angiography (QCA of entire coronary tree) IVUS + NIRS (blinded) (prox 6-8 cm of each coronary artery)








PROSPECT II Study PROSPECT ABSORB RCT



## 900 pts with ACS after successful PCI


#### 3 vessel IVUS + NIRS (blinded)

≥1 IVUS lesion with ≥65% plaque burden present?





### infraredx



The **PREVENT**ive Implantation of Bioresorbable Vascular Scaffold on Stenosis With Functionally Insignificant Vulnerable Plaque

# SJ Park PREVENT Trial Any Epicardial Coronary Stenosis with <u>FFR ≥0.80</u> and with <u>Two</u> of the following

- 1. IVUS MLA≤4.0mm<sup>2</sup>
- 2. IVUS Plaque Burden >70%
- 3. Lipid-Rich Plaque on NIRS (<sub>max</sub>LCBI<sub>4mm</sub>>500)
- 4. OCT-TCFA or VH-TCFA

**BVS+OMT** 

N=1000

Primary endpoint at 2 years: CV death, MI, Hospitalization d/t unstable angina OCT sub-study/ NIRS sub-study, (300 patients in each arm at 2 years)

OMT

N=1000

# Summary

- 1. By OCT, we can see *in vivo* pathology and we have been learning more about the pathophysiology of thrombotic events.
- 2. We believe that OCT-guided PCI is noninferior to IVUS guidance and have started a randomized trial to prove this.
- 3. An accumulation of data shows the relationship between NIRS and clinical outcomes. On-going prospective studies will provide a definitive answer.



